Reader in Biochemistry and Cell Biology
I have a keen interest in identifying targets for the immunotherapy of cancer. Currently we are developing DNA vaccines for the treatment of haematological malignancies in clinical trials. My group have identified a number of biomarkers that can indicate how patients will respond to treatment which may allow the development of personalised therapies and hopefully more effective treatments in the future.
Other References
Qualifications
- BSc Genetics - University of Aberystwyth
- Ph.D. Medicine - University of Wales College of Medicine, Wales
Teaching Expertise
- Undergraduate biochemistry (L1)
- Haematology (L2) and Human Genetics (L3)
- Masters level cancer and therapy, nucleic acid therapies
- Undergraduate and postgraduate lab-based project students
Research Interests
- Development of DNA vaccines
- Identification of tumour antigens
- Identification of biomarkers
- Analysis of tumour antigen specific T cell populations in cancer patients
Research Projects
- Identification of tumour antigens in colon cancer
- Identification of tumour antigens in ovarian cancer
- Identification of tumour antigens in acute lymphocytic leukaemia
- Development of DNA vaccines for haematological malignancies
- Simultaneous analysis of T cell populations in cancer patients using the pMHC array
- Analysis of SSX2IP as an immunotherapeutic target
Publications
Last 5 years:
- Smits E, Lee C, Hardwick N, Brooks SE, van Tendeloo VFI, Orchard K, Guinn BA. (2011) Clinical evaluation of cellular immunotherapy in acute myeloid leukaemia. Cancer Immunology, Immunotherapy, 60, 757-769.
- Lee CH, Guinn BA, Brooks SE, Richardson D, Orchard K. (2010) CD66a (CEACAM1) is the only CD66 variant expressed on the surface of plasma cells in multiple myeloma: a refined target for radiotherapy trials. British Journal of Haematology, 149, 795-797.
- Cheuk ATC, Wells JW, Chan L, Westwood NB, Berger SA, Yagita H, Okumura K, Farzaneh F, Mufti GJ, Guinn BA. (2009) Anti-tumour immunity in a model of acute myeloid leukaemia. Leukemia and Lymphoma, 50, 447-454.
- Guinn BA, Greiner J, Schmitt M, Mills KI. (2009) Elevated expression of the leukaemia associated antigen SSX2IP predicts good survival in acute myeloid leukaemia patients who lack detectable cytogenetic rearrangements. Blood, 113, 1203-1204.
- Mohamedali A, Guinn BA, Sahu S, Thomas NSB, Mufti GJ. (2009) Serum profiling reveals distinctive proteomic markers in the serum from chronic myeloid leukaemia patients. British Journal of Haematology, 144, 263-265.
- Greiner J, Bullinger L, Guinn BA, Dohner H, Schmitt M. (2008) Leukemia-associated antigens are critical for the proliferation of acute myeloid leukemia cells. Clinical Cancer Research, 14, 7161-7166.
- Guinn BA, Bullinger L, Thomas NSB, Mills KI, Greiner J. (2008) SSX2IP expression in acute myeloid leukaemia: an association with mitotic spindle failure in t(8;21), and cell cycle in t(15;17) patients. British Journal of Haematology, 140, 250-251.
- Breslin A, Denniss FAK, Guinn BA. (2007) SSX2IP: An emerging role in cancer. Biochemical and Biophysical Research Communications, 363, 462-465.
- Denniss FAK, Breslin A, Ingram WI, Hardwick NH, Mufti GJ, Guinn BA. (2007) The leukaemia associated antigen, SSX2IP, is expressed during mitosis on the surface of myeloid leukaemia cells. British Journal of Haematology, 138, 668-669.
- Guinn BA, Kasahara N, Farzaneh F, Habib NA, Norris JS, Deisseroth AB. (2007) Recent advances and current challenges in tumour immunology and immunotherapy. Molecular Therapy, 15, 1065-1071.
- Guinn BA,Mohamedali A, Thomas NSB, Mills KI. (2007) Immunotherapy of myeloid leukaemias. Cancer Immunology, Immunotherapy,56, 943-957.
- Guinn BA, Mohamedali A, Mills KI, Czepulkowski B, Schmitt M, Greiner J. (2007) Leukemia associated antigens: their dual role as biomarkers and immunotherapeutic targets for acute myeloid leukemia. Biomarker Insights, 2, 69-79.
- Guinn BA, Tobal K, Mills KI. (2007) Comparison of the survival implications of tumour-associated versus cancer-testis antigen expression in acute myeloid leukaemia. British Journal of Haematology, 136, 510-512.
